PT - JOURNAL ARTICLE AU - Nerea Montes AU - Èlia Domènech AU - Sílvia Guerrero AU - Bárbara Oliván-Blázquez AU - Rosa Magallón-Botaya TI - Analysis of cell-mediated immunity in people with long COVID AID - 10.1101/2021.06.09.21258553 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.09.21258553 4099 - http://medrxiv.org/content/early/2021/06/13/2021.06.09.21258553.short 4100 - http://medrxiv.org/content/early/2021/06/13/2021.06.09.21258553.full AB - Introduction The objective of this study is to analyse the specific immune response against SARS-CoV-2 in those affected by Long Covid (LC), attributable to T cells (cell-mediated immunity) and to carry out a parallel analysis of the humoral response and lymphocyte typing.Methodology Descriptive cross-sectional study of 74 patients with LC for at least 4 months since diagnosis. The collected data were: information on the COVID-19 episode and the persistent symptoms, medical history and a specific cell-mediated immunity to SARS-CoV-2 through flow cytometry, assessing the release of interferon-gamma (IFN-Ɣ) by T4 lymphocytes, T8 lymphocytes and NK cells. Descriptive and comparative analyses were carried out.Results Patients with LC had negative serology for Covid-19 in 89% of cases but 96% showed specific cellular immunity to SARS-CoV-2 an average of 9.5 months after infection: 89% of this response corresponded to T8 lymphocytes, 58% to NK cells, and 51% to T4 lymphocyte (20% negligibly positive). Most of them had altered immune cell typing and we found that T4 lymphocyte counts were low in 34% of cases and NK cell high in 64%. Macrophage populations were detected in the peripheral blood of 7% of them. Patients displayed a higher percentage of illnesses related to &[Prime]abnormal&[Prime] immune responses, either preceding SARS-CoV-2 infection (43%) or following it in 23% of cases.Conclusion The immune system appears to have an important involvement in the development of LC and viral persistence could be the cause or consequence of it. Further analysis with a control group should be performed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was granted for this study. Serologic tests were funded by each of the participants themselves. Participants have not received any financial benefit and took part in this study in order to further research into LC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Protocol was approved by the Clinical Research Ethics Committee of Institute of Research of Aragon, IIS-Aragon (protocol code PI21/278).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors assert that all procedures contributing to this work comply with the ethical standards of the Helsinki Declaration of 1975, as revised in 2008. All data were collected anonymously.